九联科技公告，股东胡嘉惠拟通过集中竞价或大宗交易等方式合计减持不超过600万股，占公司总股本 的1.2000%。股东许华拟减持不超过400万股，占公司总股本的0.8000%。股东凌俊拟减持不超过250万 股，占公司总股本的0.5000%。股东梁文娟、刘文燕、郑广平拟减持不超过43.06万股，不超过公司股份 总数的0.0861%。股东邱星明、何云华拟减持不超过13万股，不超过公司股份总数的0.0260%。 ...

| | 2024 年 | 2023 年 | 本年比上年增减 | 2022年 | | --- | --- | --- | --- | --- | | 营业收入(元) | 973,451,024.19 | 809,042,318.66 | 20.32% | 751,421,131.13 | | 归属于上市公司股东的净利 润(元) | -4,746,004.10 | 8,145,797.80 | -158.26% | 31,287,571.97 | | 归属于上市公司股东的扣除 非经常性损益的净利润 | -2,482,721.09 | -13.864.268.92 | 82.09% | 16,287,697.99 | | ( 71. ) | | | | | | 经营活动产生的现金流量净 | -177,806,653.03 | 119,979,972.72 | -248.20% | -107,497,095.65 | | 额(元) | | | | | 中国经济网北京7月4日讯安诺其（300067）(300067.SZ)昨晚发布关于控股股东、实际控制人的一致行动人及监事减持股份预披露公告。公 司近日收到控股股东、实际控 ...

Core Points - The major shareholder, Shenzhen Anyan Investment Partnership, plans to reduce its stake in Funeng Technology by up to 12,221,039 shares, which represents no more than 1% of the company's total share capital [1] - The reduction will occur through block trades and/or centralized bidding within three months after the announcement, starting from 15 trading days post-announcement [1] - Shenzhen Anyan currently holds 137,327,573 shares, accounting for 11.237% of the total shares [1] Shareholder Information - The shareholder, Shenzhen Anyan Investment Partnership, is a significant shareholder holding more than 5% of the company's shares [1] - There are no other arrangements or agreements with other parties regarding this reduction [1][2] - The shares to be reduced were acquired prior to the IPO [1] Reduction Plan Details - The planned reduction period is from July 25, 2025, to October 25, 2025 [1] - The reason for the reduction is stated as the shareholder's need for funds [1] - The shareholder has committed to comply with relevant regulations regarding share reduction [2][3]

Group 1 - The major shareholder, Tian Tai Rui Ju Equity Investment Center (Limited Partnership), holds 9,450,000 shares, accounting for 6.67% of the total share capital of Zhejiang Natural Outdoor Products Co., Ltd [1] - The shareholder plans to reduce its holdings by up to 1% of the total shares, which is equivalent to 1,415,730 shares, through centralized bidding within three months starting from 15 trading days after the announcement [1] - The reason for the reduction is due to the personal funding needs of some partners [1] Group 2 - The reduction plan will not lead to a change in the control of the listed company [4] - The actual controller of the company has committed not to reduce shares through Tian Tai Rui Ju Equity Investment Center [2] - The reduction plan complies with relevant laws and regulations, and the company will ensure that shareholders adhere to legal and regulatory requirements during the reduction period [4]

7月1日-3日三个交易日内，A股上市公司累计发布90多份关于公司股东减持的公告。最新公告显示，品 渥食品的股东吴柏赓在2025年6月5日至2025年7月2日通过大宗交易累计减持89.6万股，占公司总股本的 0.90%。 回顾今年上半年，东方财富Choice数据显示，A股上市公司重要股东减持金额累计约为1369.03亿元，净 减持金额约为721.42亿元。 在A股市场，股东减持一直是投资者高度关注的焦点。减持行为不仅牵动市场神经，更对公司治理、市 场生态及投资者信心产生直接影响。 业内人士指出，"合理的减持有助于市场资金的流动性和资源配置，从长期来看，不会对整体市场趋势 产生根本性影响。但如果大规模的减持集中出现，可能会在短期内对市场资金面造成一定压力，尤其是 对于一些小盘股和高估值股票，影响更为明显。" 同样在5月，证监会发布的2024年执法情况综述中提到，证监会紧盯"关键少数"失责，快查快办14起违 规减持案件,其中,中核钛白实际控制人王某龙等利用衍生品、融券等交易工具"绕道"减持,被处以2.35亿 元罚没款。 电子行业企业遭减持居多，澜起科技被股东减持套现超10亿元 从行业分布来看，东方财富Choice数 ...

威唐工业(300707.SZ)公告称，公司控股股东、实际控制人、董事长兼总经理张锡亮计划减持不超过170 万股，占总股本剔除 回购专用账户中股份数量后的0.9727%；一致行动人、董事钱光红计划减持不超过 170万股，占总股本剔除回购专用账户中股份数量后的0.9727%。减持原因为自身资金安排，股份来源 为首次公开发行前已发行的公司股份及公司资本公积金转增股份。 ...

【导读】东方雨虹实控人李卫国拟减持不超1.94%的股份，预计套现约5亿元 中国基金报记者 南深 7月2日深夜，曾经的防水材料龙头、有"防水茅"之称的东方雨虹，其实控人又抛出减持计划。 公告显示，持有东方雨虹5.31亿股（占公司总股本的22.22%）的控股股东、实际控制人李卫国计划在公告披露之日起15个交易日后的3个月内，以大宗交 易和/或集中竞价交易方式减持公司股份不超过4638.22万股（占公司总股本的比例不超过1.94%）。按7月3日收盘价计，此番减持预计可套现约5亿元。 公告称减持目的为偿还债务 对于此次李卫国的减持原因，公告称"主要用于偿还债务"，拟减持股份来源则基本是其首次公开发行股票并上市前已持有的股份（包括首次公开发行股票 后资本公积转增股本部分）。 记者注意到，目前李卫国的持股质押用于融资的比例相当高，甚至出现了展期的情况。2025年5月22日东方雨虹发布的公告显示，李卫国持有的4857.4万 股股份（约占总股本的2%）原定于4月18日质押到期，但其没有归还，而是展期一年到2026年4月17日，质押权利人是中金财富证券。 公告还显示，未来一年内，李卫国、李兴国（主要是李卫国）到期的质押股份累计 ...

【导读】东方雨虹实控人李卫国拟减持不超 1.94% 的股份，预计套现约 5 亿元 中国基金报记者 南深 7 月 2 日深夜，曾经的防水材料龙头、有 " 防水茅 " 之称的东方雨虹，其实控人又抛出减持 计划。 公告显示，持有东方雨虹 5.31 亿股（占公司总股本 的 22.22% ）的控股股东、实际控制人 李卫国计划在公告披露之日起 15 个交易日后的 3 个月内，以大宗交易和 / 或集中竞价交易 方式减持公司股份不超过 4638.22 万股（占公司总股本 的 比例不超过 1.94% ）。按 7 月 3 日收盘价计，此番减持预计可套现约 5 亿元。 公告称减持目的为偿还债务 对于此次李卫国的减持原因， 公告称 " 主要用于偿还债务 " ，拟减持股份来源则基本是其首 次公开发行股票并上市前已持有的股份（包括首次公开发行股票后资本公积转增股本部 分）。 记者注意到，目前李卫国的持股质押用于融资的比例相当高，甚至出现了展期的情况。 2025 年 5 月 22 日东方雨虹发布的公告显示，李卫国持有的 4857.4 万股股份（约占总股本的 2% ）原定于 4 月 18 日质押到期，但其没有归还，而是展期一年到 2026 ...

麦克奥迪（300341）公告，公司持股5%以上的股东香港协励行有限公司计划在减持计划预披露公告披 露之日起15个交易日后的三个月内以集中竞价或大宗交易方式减持公司股份1241.78万股，占公司总股 本比例2.4%。近日，公司收到股东香港协励行有限公司出具的《关于权益变动触及1%的告知函》。香 港协励行有限公司通过集中竞价交易方式减持公司无限售条件流通股404.41万股，通过大宗交易方式减 持公司无限售条件流通股181.15万股。本次权益变动后，香港协励行有限公司持有公司股份4272.14万 股，占公司总股本的比例为8.26%。 ...

Core Viewpoint - The company, He Shi Eye Hospital, is facing significant challenges, including a substantial decline in stock price and ongoing shareholder reduction pressures, amid a competitive landscape in the ophthalmology industry [1][3][7]. Company Summary - He Shi Eye Hospital's major shareholder, Advanced Manufacturing Industry Investment Fund, plans to reduce its holdings by up to 3.1061 million shares, representing 2% of the total share capital, marking the second attempt for a similar reduction [3]. - The company's stock price has dropped over 60% from its historical peak, closing at 21.82 yuan per share as of July 2, 2025 [1][3]. - Since its establishment in 1995, He Shi Eye Hospital has expanded from a small clinic to a group-based ophthalmology service provider, currently operating 127 service institutions as of the end of 2024 [6]. Financial Performance - In 2022, He Shi Eye Hospital reported a revenue of 9.55 billion yuan, a slight decrease of 0.74% year-on-year, with a net profit of 0.33 billion yuan, down 61.55% [7]. - The financial situation worsened in 2024, with revenue declining by 7.56% to 10.96 billion yuan and a net loss of 0.2739 billion yuan, marking a 143.11% year-on-year decline [7][8]. - Compared to competitors like Aier Eye Hospital, which maintained a revenue growth rate of around 20%, He Shi Eye Hospital has experienced negative growth since its IPO [7][9]. Industry Context - The ophthalmology market in China is undergoing significant changes, with the number of private eye hospitals increasing from 890 to 1,609 between 2019 and 2023, reflecting a compound annual growth rate of 15.4% [9]. - He Shi Eye Hospital's main business segments, including cataract, optical, and refractive services, have all faced revenue declines due to increased competition from larger players [9][10]. - The industry is also impacted by policy changes, such as the reform of medical insurance payment methods and centralized procurement of medical supplies, which have reduced procurement costs by 60% but also compressed profit margins [10].